Literature DB >> 28066005

Metabolic syndrome and central obesity in depression: A cross-sectional study.

Anju Agarwal1, Manu Agarwal2, Kabir Garg2, Pronob Kumar Dalal2, Jitendra Kumar Trivedi2, J S Srivastava3.   

Abstract

INTRODUCTION: The current epidemiological data and meta-analyses indicate a bidirectional association between depression and metabolic syndrome (MetS). AIMS: To assess the prevalence of metabolic syndrome and obesity in drug naïve patients (in current episode) having Recurrent Major Depressive Disorder and Bipolar Depression.
METHOD: This was a single point cross sectional observational study that involved administration of diagnostic and assessment tools and blood investigations. Recruitment for the study was done from a period of September 2008 to august 2009.
RESULTS: The prevalence of MetS was significantly more in the depression group when compared to healthy controls. The Bipolar depression group had 24% prevalence and recurrent depression group had 26% prevalence as opposed to none in the control group. The prevalence of MetS did not differ significantly amongst the both depression groups. Presence of central obesity was significantly more in the recurrent depression (30%) and Bipolar depression (24%) as compared to controls (8%). There was no statistically significant difference between the two depression subgroups. DISCUSSION: Our study adds to the mounting evidence that links the presence of depression and metabolic syndrome. As we had ensured a drug free period of at least 3 months, the findings in our study indicate that the metabolic syndrome observed in our study is independent of drug exposure.
CONCLUSIONS: This study demonstrated significantly more incidence of metabolic syndrome and central obesity in patients of depression than age and sex matched controls.

Entities:  

Keywords:  Central obesity; depression; metabolic syndrome; obesity

Year:  2016        PMID: 28066005      PMCID: PMC5100119          DOI: 10.4103/0019-5545.192021

Source DB:  PubMed          Journal:  Indian J Psychiatry        ISSN: 0019-5545            Impact factor:   1.759


INTRODUCTION

Metabolic syndrome (MetS) is a set of metabolic, anthropometric, and hemodynamic abnormalities including abdominal obesity, impaired lipid profile (lowered high density lipoprotein [HDL] and elevated triglycerides), hypertension, and impaired fasting glucose or insulin resistance.[1] Studies done on Western populations have pegged the prevalence at approximately one-third of the general population.[23] Similar studies in Indian populations have found comparable prevalence, ranging from 31 to 41% of studied adults, with greater prevalence in women.[45] Needless to say, the risk factors considered under MetS can cause significant physical impairments and adverse health outcomes, Type 2 diabetes and cardiovascular morbidity being the best established ones.[6] It has also been associated with increasing the risk of mortality due to cardiovascular events and also an overall, all-cause increase in mortality in the general population.[57] MetS has also been associated robustly with a number of psychiatric illnesses, including and in no ways limited to bipolar disorder, depression, and schizophrenia across multiple studies all around the globe.[89101112131415] The current epidemiological data and meta-analyses indicate a bidirectional association between depression and MetS.[16] It should also be noticed that a majority of the studies in this area focus on MetS as a whole, using a dichotomous outcome variable,[17] which strongly varies among different treatment centers and settings. In a British study, it was demonstrated that MetS, and more importantly, its obesity and hyperlipidemia components predicted the development of depressive symptoms over a follow-up period of 6 years.[18] Another meta-analysis involving 5000 depressed subjects calculated the estimated mean prevalence of MetS to be up to 30.5%.[19] In another population-based study, women with MetS in their childhood were found to have increased levels of depressive symptoms in adulthood, and the severity of these symptoms increased in proportion to the duration of exposure to MetS over lifetime.[20] Consequently, studies have found MetS to be a possible predisposing factor for the development of depression, and subsequently, have raised questions whether investigating individual components besides MetS per se would be useful.[16] There has also existed some amount of debate over whether some of the metabolic parameters comprising MetS are more predictive for depressive disorders than others.[16] Of the five components, waist circumference (i.e. abdominal obesity) has been found to be the strongest predictor.[20] Hypertriglyceridemia and low HDL have also been associated to a fair degree, but the association with hyperglycemia and hypertension have been studied to a lesser degree and the results have also been contradictory.[202122] As was discussed that a bidirectional association has been observed, data also exist regarding the risk for developing MetS in patients of depression. Follow-up studies have found increased the incidence of MetS and its components in patients of depression. It has also been found that the severity of depression is positively associated with the metabolic outcomes in outpatients and also the use of Anti-depressant medications.[1723] At the same time, multiple studies have shown poorer outcomes in depressive illnesses in patients with concomitant MetS or obesity.[162425] To the best of our knowledge, however, we could not find a study where MetS or its parameters were compared among the two major diagnoses of depression, namely the recurrent and the bipolar depression along with healthy controls.

METHODS

This was a single-point cross-sectional observational study that involved administration of diagnostic and assessment tools and blood investigations. Recruitment for the study was done from September 2008 to August 2009 from the adult psychiatric Outpatient Services of our Department. Men and women aged between 18 and 50 years were eligible for the study. We excluded patients above 50 years of age to exclude the effects of age on the metabolic parameters (such as blood glucose, lipid profile, and blood pressure). A drug-free period of 3 months was also ensured as to allow time for the parameters of MetS, which may be altered by psychotropic medications[2627] to return to premedication levels. Pregnant or currently lactating women were excluded from the study. We excluded patients with co-morbid physical illnesses (such as coronary artery disease, hypothyroidism, liver or kidney disorders) or receiving medications (including contraceptive pills) that may alter the MetS parameters, and patients with any other co-morbid axis-I disorder were excluded as the current study focused on recurrent and bipolar depression. All the subjects provided written informed consent and the study was approved by the Institutional Ethics Committee. The study comprised three groups, two groups comprised of age and sex matched patients of bipolar depression and recurrent depression. The third group comprised of age and sex matched healthy controls. The subjects were evaluated for the MetS based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III)[28] criteria.

Assessment of components of metabolic syndrome

Blood pressure was measured using a mercury sphygmomanometer in a well-rested subject in the left arm in the sitting position at two occasions, once at initial physical examination and the other on the following morning, and an average of the two was recorded. The body measurements for height, waist and hip circumference, weight and body mass index were done by the investigator (AB) using standard procedures. Participants were asked to fast overnight, following which 5 ml of venous blood was collected by standard venipuncture, 2 ml transferred to fluoride vial and 3 ml to non-ox vial for estimation of serum glucose and lipid levels, respectively. These vials were transferred to the lab immediately following standard preservation practices, and the sample was centrifuged and analyzed for blood glucose, serum HDL, and serum triglycerides on the same day, using automated analyzer (Roche Diagnostics, UK). The diagnostic criteria that were used for the MetS were the updated NCEP ATP III criteria,[29] which include cut-offs for waist circumference (males ≥90 cm, females ≥80 cm), fasting blood glucose (≥100 mg/dl), triglycerides (≥150 mg/dl), blood pressure (≥135/≥80 mm Hg), and low HDL (males <40 mg/dl and females <50 mg/dl). The NCEP ATP III criteria have ethnic specific cut-offs and these cut-offs are identical to the ones that are recommended for use in Indian population by the expert consensus statement on the issue.[30] Three or more of these parameters have to be abnormal for a diagnosis of MetS to be made in an individual.

Evaluation for psychiatric and physical disorders

The diagnosis of depression was made as per the criteria of Diagnostic and Statistical Manual of Mental Disorders 4th Edition, Text Revision (DSM-IV-TR).[31] The subjects were evaluated on the Structure Clinical Interview on DSM-IV-TR[32] for making Axis-I diagnosis of a recurrent depression or bipolar depression in accordance with and also to rule out any other psychiatric co-morbidity. The included participants were rated on the 17-item Hamilton Depression Rating Scale (HAM-D)[33] and Clinical Global Impression Scale[34] (only Severity scale was used as it was a single point study). The Global Assessment of Functioning Scale[35] was used to assess the participants’ psychological, social, and occupational functioning.

Statistical analyses

The three participant groups were compared on the sociodemographic variables including age, gender, marital status, domicile, religion, and monthly family income using the Pearson Chi-squared test. The numbers of subjects having MetS and central obesity in each group were compared using the Pearson Chi-squared test, and the correlation between waist circumference and severity of depression on HAM-D was assessed by calculating Pearson's Co-relation coefficient. The data were tabulated and results were calculated using Statistical Package for the Social Sciences (SPSS) version 14.0.0 for windows.

RESULTS

Crude demographic and clinical variables of the three groups are shown in Table 1. No statistically significant difference exists between the groups. Majority of the patients were males, between ages 31 and 40 years, married, and from rural background and lower socioeconomic class.
Table 1

Sociodemographic details of the sample

Sociodemographic details of the sample The presence of MetS is shown in Table 2. The prevalence of MetS was significantly more in the depression group when compared to healthy controls. The bipolar depression group had 24% prevalence and recurrent depression group had 26% prevalence as opposed to none in the control group. The prevalence of MetS did not differ significantly among both the depression groups.
Table 2

Presence of metabolic syndrome

Presence of metabolic syndrome Presence of central obesity was significantly more in the recurrent depression (30%) and bipolar depression (24%) as compared to controls (8%). There was no statistically significant difference between the two depression subgroups [Table 3].
Table 3

Presence of central obesity

Presence of central obesity The waist circumference was also positively correlated with the severity of depressive symptoms as measured on the HAM-D scale (r = 0.291; P = 0.003).

DISCUSSION

Our study shows that MetS was more prevalent in the patients suffering from depressive episode when compared to healthy controls (P < 0.01). While no subject from the control group had MetS, the difference among the two patient groups was not statistically significant. As we had ensured a drug-free period of at least 3 months, the findings in our study indicate that the MetS observed in our study is independent of drug exposure. Our study adds to the mounting evidence that links the presence of depression and MetS. In the studies done in the Western populations, investigators have found that a current or lifetime diagnosis of depression increases the risk of MetS.[36] Similarly, in studies comparing patients suffering from depression to healthy controls, increased prevalence of MetS was established.[10111315] In a meta-analyses on MetS and metabolic abnormalities in patients of depression, comprising 18 studies and 5531 subjects, a mean prevalence of 29.7% was reported.[19] This is comparable to the prevalence found in our patients group (26% in recurrent depression and 24% in bipolar depression group). In another study done on drug-naive patients[37] of depression in India, the prevalence of MetS was found to be significantly higher (37.2%) than healthy controls. While the association between MetS and depression has been firmly demonstrated, the question of causality, however, still stands inadequately answered. There have been studies on the predisposing role of MetS in depressive disorder. A longitudinal study found that subjects with no psychiatric illness and MetS at baseline were twice more likely to develop depressive symptoms during follow-up than their healthy matched controls.[38] This area is of particular concern as if MetS is established as a predisposing factor, its subsequent prevention, and treatment can also be an important step in the prevention of depression. Nevertheless, the high co-occurrence of depressive symptoms and MetS is highly indicative of a patho-physiological overlap between the two conditions. While the conclusive evidence and mechanism are yet to be elucidated, the proposed hypotheses include elevation in cortisol secretion due to increased activity of HPA axis, neuro-inflammatory processes involving interleukin-6 and C-reactive protein, increased oxidative stress, autonomic dysregulation in form of increased sympathetic and decreased parasympathetic system responses, and insulin resistance.[19] It should also be remembered that even if the biological processes are important, equally relevant are the lifestyle and socio-economic factors.[1339] Depression is known to be associated with increasing odds of developing hyperglycemia and hypertriglyceridemia, which may be attributed to the biological process of depression or the associated changes in the diet and physical activity.[40] We also compared the individual metabolic abnormalities in our participant groups. In our study, visceral obesity (increased waist circumference) was significantly more in the recurrent depression patient groups compared to the healthy controls. This has been reported in many of the studies.[243741424344] Over the last 10–15 years, an increasing amount of literature has appeared, examining the cross-sectional and longitudinal relationship between the constructs of obesity and depression. While a large number of these studies have defined obesity by BMI, which is an indicator of general fat distribution.[40454647] The abdominal fat or visceral obesity is known to have a greater impact on the immune system and is considered to have greater predictive value for health outcomes.[48] In addition, as discussed earlier, association between central obesity as a MetS variable has a stronger association with depression,[20] thus studies have made use of abdominal obesity as a variable. As reported in a meta-analysis, a significant degree of association between obesity and depression has been found in multiple community studies.[45] Its findings were in concordance with the meta-analysis on relation of abdominal obesity with depression where the risk of having depression was increased by more than 50% in obese men and women.[48] Furthermore, the mean waist circumference of recurrent major depressive disorder (77.18 ± 8.79) and bipolar depression (77.68 ± 9.16) was significantly higher (P = 0.03; P = 0.02) as compared to control group (73.92 ± 6.66). There was no significant difference in the prevalence of obesity between the recurrent depression and the bipolar depression group. However, association of obesity has been more robustly defined with bipolar disorder than depression.[4950] An important confounding factor in many studies has been the medications for the treatment of bipolar disorder, such as lithium, valproic acid, and atypical antipsychotics that have been associated with weight gain.[5152535455] Some of the unanswered questions include whether severity of depression influences the obesity. There has been some evidence that depression increases with severity of obesity.[5657] In our sample too, we found a positive correlation, albeit small between the severity of depression on HAM-D and the mean waist circumference. A very important query in relation to obesity, as with MetS, is the existence of a causal link. There have been some studies that have found evidence that depression predicts development of obesity,[5859] a recent met-analysis has also concluded that depression can predict development of obesity later in life.[46] On the other hand, there have been studies that have found that obesity may predict the development of depression.[6061] Nevertheless, the findings of our study are clinically important, as it is imperative for us as clinicians to identify patients having or predisposed to MetS and obesity. While some longitudinal and cross-sectional studies have found gender to be a factor, meta-analyses have not shown any significant differences, indicating that both the sexes need equal attention. It is also important because depression and associated biological/psychological processes may take more salience than the known risk factor of age for MetS,[62] as suggested by the age of our sample, which was on the lower side. This finding was also found in the meta-analyses on the subject.[1948] Thus, it can be suggested that individuals with depressive disorder can be screened for MetS risk factors, and this approach should not just be reserved for patients of advanced age, but also the younger age group patients. Another important step in this direction can be the management of these individuals as a multi-disciplinary collaborative effort between the psychiatrist and physicians, with psychoeducation and motivation for lifestyle improvements and use of lower risk medications or medications to reduce the weight or metabolic abnormalities.[63] Our study did have a number of limitations. Our sample size was small and thus results may not be generalized to general population. In addition, the cross-sectional design of the study is not suitable to demonstrate prognostic or predictive features of the MetS or its variables. Longitudinal studies are required to study these areas and also the impact of intervention on metabolic parameters in patients suffering from depression.

CONCLUSION

In the current study, the overall prevalence of MetS was found to be 25% in the patients group (24% in recurrent depression and 26% in bipolar depression), which was significantly more than the healthy age- and sex-matched controls. Central obesity was also present in significantly higher proportion of the patient groups, and the waist circumference was found to be positively associated with the severity of depressive symptoms.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  59 in total

1.  Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use.

Authors:  A K B van Reedt Dortland; E J Giltay; T van Veen; F G Zitman; B W J H Penninx
Journal:  Acta Psychiatr Scand       Date:  2010-04-26       Impact factor: 6.392

2.  Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study.

Authors:  A Herva; J Laitinen; J Miettunen; J Veijola; J T Karvonen; K Läksy; M Joukamaa
Journal:  Int J Obes (Lond)       Date:  2006-03       Impact factor: 5.095

Review 3.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Prevalence of overweight and obesity in bipolar patients.

Authors:  J L Elmslie; J T Silverstone; J I Mann; S M Williams; S E Romans
Journal:  J Clin Psychiatry       Date:  2000-03       Impact factor: 4.384

5.  Prospective association between obesity and depression: evidence from the Alameda County Study.

Authors:  R E Roberts; S Deleger; W J Strawbridge; G A Kaplan
Journal:  Int J Obes Relat Metab Disord       Date:  2003-04

Review 6.  Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies.

Authors:  Floriana S Luppino; Leonore M de Wit; Paul F Bouvy; Theo Stijnen; Pim Cuijpers; Brenda W J H Penninx; Frans G Zitman
Journal:  Arch Gen Psychiatry       Date:  2010-03

7.  Metabolic syndrome: a follow-up study of acute depressive inpatients.

Authors:  N Richter; G Juckel; H-J Assion
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-04-28       Impact factor: 5.270

8.  Co-occurrence of metabolic syndrome with depression and anxiety in young adults: the Northern Finland 1966 Birth Cohort Study.

Authors:  Anne Herva; Pirkko Räsänen; Jouko Miettunen; Markku Timonen; Kristian Läksy; Juha Veijola; Jaana Laitinen; Aimo Ruokonen; Matti Joukamaa
Journal:  Psychosom Med       Date:  2006 Mar-Apr       Impact factor: 4.312

9.  Association between adolescent emotional problems and metabolic syndrome: the modifying effect of C-reactive protein gene (CRP) polymorphisms.

Authors:  Darya Gaysina; Mary Pierce; Marcus Richards; Matthew Hotopf; Diana Kuh; Rebecca Hardy
Journal:  Brain Behav Immun       Date:  2011-02-04       Impact factor: 7.217

10.  Drug-emergent metabolic syndrome in patients with schizophrenia receiving atypical (second-generation) antipsychotics.

Authors:  Shiv Gautam; Parth Singh Meena
Journal:  Indian J Psychiatry       Date:  2011-04       Impact factor: 1.759

View more
  7 in total

1.  Increased expression of plasminogen activator inhibitor-1 (PAI-1) is associated with depression and depressive phenotype in C57Bl/6J mice.

Authors:  René A Girard; Prashant S Chauhan; Torry A Tucker; Tim Allen; Jaswinder Kaur; Ann Jeffers; Kathleen Koenig; Galina Florova; Andrey A Komissarov; Tatiana A Gaidenko; Mignote B Chamiso; James Fowler; Danna E Morris; Krishna Sarva; Karan P Singh; Steven Idell; Richard D Idell
Journal:  Exp Brain Res       Date:  2019-11-16       Impact factor: 1.972

2.  Association of Inflammatory and Liver Markers with Cardiometabolic Risk Factors in Patients with Depression.

Authors:  Naresh Nebhinani; Praveen Sharma; Vrinda Pareek; Navratan Suthar; Shobhan Jakhotia; Mukesh Gehlot; Purvi Purohit
Journal:  Indian J Clin Biochem       Date:  2018-02-15

3.  Age is a number, not a group.

Authors:  Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2017 Apr-Jun       Impact factor: 1.759

4.  Association between depression and metabolic syndrome: Critical issues and missed opportunities.

Authors:  Abhishek Ghosh; Damodharan Dinakaran; Naresh Nebhinani; Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2017 Apr-Jun       Impact factor: 1.759

5.  Prevalence of Metabolic syndrome among adults in a teaching hospital in Kochi, Central Kerala: A cross-sectional study.

Authors:  Rose Mary J Vatakencherry; L Saraswathy
Journal:  J Family Med Prim Care       Date:  2019-06

6.  The combined effect of socioeconomic status and metabolic syndrome on depression: the Korean National Health and Nutrition Examination Survey (KNHANES).

Authors:  B Kim; E Y Park
Journal:  BMC Public Health       Date:  2020-05-04       Impact factor: 3.295

7.  The relationship between depression and risk of metabolic syndrome: a meta-analysis of observational studies.

Authors:  Yousef Moradi; Ahmed N Albatineh; Hassan Mahmoodi; Reza Ghanei Gheshlagh
Journal:  Clin Diabetes Endocrinol       Date:  2021-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.